UBS lowered the firm’s price target on Arrowhead (ARWR) to $63 from $71 and keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals: Strong Financial Position with Pipeline Uncertainties Justifying Hold Rating
- Arrowhead Pharmaceuticals: Hold Rating Amid Promising Developments and Regulatory Uncertainties
- Arrowhead price target lowered to $17 from $21 at Citi
- Hold Rating for Arrowhead Pharmaceuticals Amid Revenue Gains and Market Uncertainties
- Arrowhead Pharmaceuticals Reports Strong Q2 2025 Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue